CoChat

Exenatide once weekly for the treatment of type 2 diabetes

Malone, James, Trautmann, Michael, Wilhelm, Ken, Taylor, Kristin, Kendall, David M · 2009 · Expert Opinion on Investigational Drugs

The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.

Abstract

Exenatide is the first glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus (T2DM). Exenatide lowers blood glucose through multiple mechanisms, including enhancement of glucose-dependent insulin secretion, suppression of excess glucagon secretion, reduction of food intake and slowing of gastric emptying. The current formulation of exenatide requires twice-daily dosing (exenatide BID), and an extended-release formulation of exenatide is now in development for use as a once-weekly injection (exenatide QW). The purpose of this report is to review the most current clinical data on the development of exenatide QW for the treatment of T2DM. In clinical trials, exenatide QW significantly improved glycemic control, resulted in patient weight loss, and was well tolerated in patients with T2DM. In a head-to-head clinical trial, exenatide QW caused greater improvements in glycemic control and was better tolerated than exenatide BID. Given the rapidly increasing prevalence of diabetes and obesity worldwide, exenatide QW is a promising development candidate for the treatment of T2DM.

Overview

Integrity signals

Registry

Crossref · 10.1517/13543780902766802

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 54 references

Research works printed but not linked: 3

  1. Ratner RE Rosenstock J Boka G. A dose-finding study of the new GLP-1 agonist AVE0010 in type 2 diabetes insufficiently controlled with metformin. Diabetes 2008;57:A129 [Abstract 433-P]
  2. Balena R Ratner R Berria R et al. Eight weeks of treatment with the long acting human GLP-1 analogue R1583 improves glycemic control and lowers body weight in subjects with type 2 diabetes mellitus (T2DM) treated with metformin: A double-blind placebo-controlled phase 2 study. Diabetes 2008;57:A33 [abstract 108-OR]
  3. Diabetes Atlas. Third edition©. International Diabetes Foundation 2006

Cited by

See all 56

Metadata

Authors
Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M.
Affiliations
  • Eli Lilly (United States) (US)
  • Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA 92121, USA
  • International Diabetes Center, 3800 Park Nicollet Blvd, Minneapolis, MN, 55416, USA
Venue
Expert Opinion on Investigational Drugs
Published
2009-03
Volume
18
Issue
3
Pages
359-367
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W1975612744
Cited by
55
References
55
Citations by year
2026: 3 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 1 · 2017: 4 · 2016: 3 · 2015: 3 · 2014: 3 · 2013: 6 · 2012: 4
FWCI
5.32
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Investigational Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
exenatide, sustained-release formulation, GLP-1 receptor agonists, type 2 diabetes, glycemic control, weight loss, insulin secretion, glucagon suppression, gastric emptying, drug tolerability
MeSH terms
Exenatide, Animals, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Tolerance, Glycated Hemoglobin, Humans, Peptides, Venoms, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exenatide once weekly for the treatment of type 2 diabetes. https://app.cochat.ai/papers/10.1517/13543780902766802
The paper
Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M. (2009). Exenatide once weekly for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543780902766802

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.